The Shifting Treatment Landscape of RRMS

Experts in neurology review recent advances in the treatment landscape of relapse-remitting multiple sclerosis (RRMS) and the ever-present challenge of tailoring treatment to individual patients.

Ravi Dukkipati, MD, and Gabriel Pardo, MD, FAAN, discuss barriers in accessing treatment for patients with RRMS, as well as a lack of appropriate biomarkers to monitor disease progression.

Expert neurologists review availability of generic disease-modifying therapies [DMTs] and the effectiveness of reduced cost to the patient with RRMS

Gabriel Pardo, MD, FAAN, describes the process that generic RRMS medications have to go through to be approved by the FDA, highlighting the abbreviated new drug application [ANDA] process.

Experts in neurology highlight factors that lead them to choose certain therapies to treat relapsing remitting multiple sclerosis (RRMS), such as high efficacy in clinical trials.

Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, consider reasons to use generic disease-modifying therapies (DMTs) as a first-line therapy in the treatment of relapsing remitting multiple sclerosis (RRMS).

Expert neurologists review treatment options for a young female with relapsing remitting multiple sclerosis (RRMS).

Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, discuss a patient case with relapsing/remitting multiple sclerosis progression and share considerations for switching treatment.

Ravi Dukkipati, MD, and Gabriel Pardo, MD, FAAN, review the use of rituximab and other disease-modifying therapies in a patient with an established diagnosis of relapsing/remitting multiple sclerosis.

Expert neurologists discuss treatment options for a patient with comorbid autoimmune diseases, relapsing/remitting multiple sclerosis, and psoriasis.

Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, comment on the use of generic DMTs in the treatment of RRMS, highlighting efficacy and safety data as well as level of equivalence to brand name treatments.

Experts in neurology provide insight on challenges that arise with the use of generic DMTs in RRMS treatment, such as cost to the patient.

Expert neurologists highlight upcoming agents for the treatment of RRMS, focusing on biomarkers.

Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, share key takeaways for clinicians treating RRMS.